ATYR
aTyr PharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATYR
Atyr Pharma, Inc.
A company that focused on researching the extracellular functionality and signaling pathways of tRNA synthetases
Biological Technology
09/08/2005
05/07/2015
NASDAQ Stock Exchange
56
12-31
Common stock
10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121
--
ATyr Pharma, Inc., was incorporated in Delaware on September 8, 2005. The company is a clinical-stage biotechnology company that uses evolutionary intelligence to transform tRNA synthetase biology into new treatments for fibrosis and inflammation. TRNA synthetases are ancient, essential proteins that have evolved new domains to regulate different pathways outside the human cell. The company's discovery platform focuses on unlocking hidden therapeutic intervention points by discovering signaling pathways driven by domain proprietary libraries derived from all 20 tRNA synthetases.
Company Financials
EPS
ATYR has released its 2025 Q3 earnings. EPS was reported at -0.26, versus the expected -0.18, missing expectations. The chart below visualizes how ATYR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ATYR has released its 2025 Q3 earnings report, with revenue of 190.00K, reflecting a YoY change of NaN%, and net profit of -25.75M, showing a YoY change of -49.16%. The Sankey diagram below clearly presents ATYR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
